tetano
Editor, Senior Moderator
Vaccine X
. 2024 Jan 20:16:100443.
doi: 10.1016/j.jvacx.2024.100443. eCollection 2024 Jan. Immunogenicity studies of recombinant RBD SARS-CoV-2 as a COVID-19 vaccine candidate produced in Escherichia coli
Intan Aghniya Safitri[SUP] 1 [/SUP], Yovin Sugijo[SUP] 2 [/SUP], Fernita Puspasari[SUP] 2 [/SUP], Fifi Fitriyah Masduki[SUP] 2 3 [/SUP], Ihsanawati[SUP] 2 [/SUP], Ernawati Arifin Giri-Rachman[SUP] 1 3 [/SUP], Aluicia Anita Artarini[SUP] 4 3 [/SUP], Marselina Irasonia Tan[SUP] 1 3 [/SUP], Dessy Natalia[SUP] 2 3 [/SUP]
Affiliations
The severe acute respiratory syndrome coronavirus 2 -related global COVID-19 pandemic has been impacting millions of people since its outbreak in 2020. COVID-19 vaccination has proven highly efficient in reducing illness severity and preventing infection-related fatalities. The World Health Organization has granted emergency use approval to multiple, including protein subunit technology-based, COVID-19 vaccines. Foreseeably, additional COVID-19 subunit vaccine development would be essential to meet the accessible and growing demand for effective vaccines, especially for Low-Middle-Income Countries (LMIC). The SARS-CoV-2 spike protein receptor binding domain (RBD), as the primary target for neutralizing antibodies, holds significant potential for future COVID-19 subunit vaccine development. In this study, we developed a recombinant Escherichia coli-expressed RBD (rRBD) as a vaccine candidate and evaluated its immunogenicity and preliminary toxicity in BALB/c mice. The rRBD induced humoral immune response from day 7 post-vaccination and, following the booster doses, the IgG levels increased dramatically in mice. Interestingly, our vaccine candidate also significantly induced cellular immune response, indicated by the incrased IFN-ɣ-producing cell numbers. We observed no adverse effect or local reactogenicity either in control or treated mice. Taken together, our discoveries could potentially support efficient and cost-effective vaccine antigen production, from which LMICs could particularly benefit.
Keywords: COVID-19; Escherichia coli; RBD; SARS-CoV-2; Vaccine candidate.
. 2024 Jan 20:16:100443.
doi: 10.1016/j.jvacx.2024.100443. eCollection 2024 Jan. Immunogenicity studies of recombinant RBD SARS-CoV-2 as a COVID-19 vaccine candidate produced in Escherichia coli
Intan Aghniya Safitri[SUP] 1 [/SUP], Yovin Sugijo[SUP] 2 [/SUP], Fernita Puspasari[SUP] 2 [/SUP], Fifi Fitriyah Masduki[SUP] 2 3 [/SUP], Ihsanawati[SUP] 2 [/SUP], Ernawati Arifin Giri-Rachman[SUP] 1 3 [/SUP], Aluicia Anita Artarini[SUP] 4 3 [/SUP], Marselina Irasonia Tan[SUP] 1 3 [/SUP], Dessy Natalia[SUP] 2 3 [/SUP]
Affiliations
- PMID: 38304876
- PMCID: PMC10832452
- DOI: 10.1016/j.jvacx.2024.100443
The severe acute respiratory syndrome coronavirus 2 -related global COVID-19 pandemic has been impacting millions of people since its outbreak in 2020. COVID-19 vaccination has proven highly efficient in reducing illness severity and preventing infection-related fatalities. The World Health Organization has granted emergency use approval to multiple, including protein subunit technology-based, COVID-19 vaccines. Foreseeably, additional COVID-19 subunit vaccine development would be essential to meet the accessible and growing demand for effective vaccines, especially for Low-Middle-Income Countries (LMIC). The SARS-CoV-2 spike protein receptor binding domain (RBD), as the primary target for neutralizing antibodies, holds significant potential for future COVID-19 subunit vaccine development. In this study, we developed a recombinant Escherichia coli-expressed RBD (rRBD) as a vaccine candidate and evaluated its immunogenicity and preliminary toxicity in BALB/c mice. The rRBD induced humoral immune response from day 7 post-vaccination and, following the booster doses, the IgG levels increased dramatically in mice. Interestingly, our vaccine candidate also significantly induced cellular immune response, indicated by the incrased IFN-ɣ-producing cell numbers. We observed no adverse effect or local reactogenicity either in control or treated mice. Taken together, our discoveries could potentially support efficient and cost-effective vaccine antigen production, from which LMICs could particularly benefit.
Keywords: COVID-19; Escherichia coli; RBD; SARS-CoV-2; Vaccine candidate.